On January 12, 2018, the Food and Drug Administration announced they expanded the approved use of the drug olaparib (brand name Lynparza). Olaparib is the first drug of its class (PARP inhibitor) approved to treat HER2-negative metastatic breast cancer in patients with a BRCA gene mutation and who have previously been treated with chemotherapy. Listen to what our Deputy Director, Joyce Bichler, had to say about the approval on San Francisco’s KCBS All-News Radio 1/12/18.

Breast Cancer Action's Deputy Director on the FDA's Expanded Approval of Olaparib (KCBS Radio)

Breast Cancer Action